fluphenazine has been researched along with Sex Disorders in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The risk of adverse side effects of neuroleptic agents must be considered carefully in the treatment of acute and long-term psychotic states." | 3.75 | Antipsychotic drug side effects: their relationship to dose. ( Kane, JM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kelly, DL | 1 |
| Conley, RR | 1 |
| Shen, WW | 1 |
| Mallya, AR | 1 |
| Gomez, EA | 1 |
| Kane, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 3.9 |
| AL-108, 5 mg/Day | 4.6 |
| Placebo | 3.2 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 1.3 |
| AL-108, 5 mg/Day | 2.3 |
| Placebo | -0.2 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | -0.4 |
| AL-108, 5 mg/Day | -1.2 |
| Placebo | -0.3 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 0.1 |
| AL-108, 5 mg/Day | -0.6 |
| Placebo | -0.1 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 4.9 |
| AL-108, 5 mg/Day | 8.9 |
| Placebo | 0.3 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 2.9 |
| AL-108, 5 mg/Day | 7.2 |
| Placebo | -0.9 |
1 review available for fluphenazine and Sex Disorders
| Article | Year |
|---|---|
Antipsychotic drug side effects: their relationship to dose.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Respon | 1985 |
2 trials available for fluphenazine and Sex Disorders
| Article | Year |
|---|---|
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
Antipsychotic drug side effects: their relationship to dose.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Respon | 1985 |
2 other studies available for fluphenazine and Sex Disorders
| Article | Year |
|---|---|
Psychotropic-induced sexual inhibition.
Topics: Adult; Benztropine; Erectile Dysfunction; Female; Fluphenazine; Humans; Male; Psychotropic Drugs; Se | 1983 |
Hypersexuality in men receiving fluphenazine decanoate.
Topics: Adult; Female; Fluphenazine; Humans; Libido; Male; Sexual Dysfunction, Physiological | 1981 |